Cidara Therapeutics, Inc. Aktie News

Bought 520,310 additional shares; position value rose by approximately $167.48 million Post-trade stake: 3,020,990 shares valued at $289.29 million CDTX is now the fund's 3rd-largest holding, accounting for approximately 19.2% of AUM

Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium to the biotech's prior trading price, the bid caused its shares to surge.

In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.

California-based TCG Crossover Management sold 1 million shares of Cidara Therapeutics, cutting its stake by approximately $49 million in the third quarter. The transaction value equaled about 2.4% of the fund's 13F assets under management at quarter-end.

Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cidara Therapeutics, Inc. (NasdaqCM: CDTX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Cidara will receive $221.50 in cash for each share of Cidar...

Shares of Cidara Therapeutics (CDTX) more than doubled Friday after Merck (MRK) agreed to buy the biopharmaceutical firm in an all-cash deal worth $9.2 billion to expand its reach in antiviral treatments.

Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.